CAMSON BIO TECHNOLOGIES LTD

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31.12.09

Rs in Lacs

Sl.No	PARTICULARS	3 months ended	corrp 3 mnt end in the prevs yr	9 months ended	corrp 9 mnt end in the prevs yr	Previous accounting year ended
		31.12.09	31.12.08	31.12.09	31.12.08	31.03.09
		(UNAUDITED)				**(AUDITED)**
1	Net Sales from Operations	2167.92	697.52	6134.25	3411.31	4941.07
	TOTAL INCOME	**2167.92**	**697.52**	**6134.25**	**3411.31**	**4941.07**
2	Expenditure					
	a) Increase/decrease in Stock in trade and work in Progress	(440.35)	41.07	(1014.47)	258.14	(289.34)
	b) Consumption of raw materials	780.45	69.31	2143.02	688.57	1654.04
	c) Purchase of traded goods	0.00	0.00	0.00	0.00	0.00
	d) Employee Cost	70.08	64.65	200.6	124.35	199.92
	e) Depreciation	42.57	28.34	115.68	75.00	102.69
	f) Other Expenditure	0.00	0.00	0.00		
	Selling and Distribution Expenses	667.96	106.32	1891.15	582.3	1308.34
	Research Expenditure	496.62	207.71	1315.6	652	1001.66
	Other Expenditure	62.22	70.31	195.65	303.96	108.83
	TOTAL (Any item exceeding 10% of the total expenditure to be shown seperately)	**1679.55**	**587.71**	**4847.23**	**2684.32**	**4086.14**
3	**Profit from operation before Interest & Exceptional items(1-2)**	**488.37**	**109.81**	**1287.02**	**726.99**	**854.93**
4	Other Income	0.32	0	0.84	4.12	0.84
5	**Profit before Interest & Exceptional items(3+4)**	488.69	109.81	1287.86	731.11	855.77
6	Interest	0.71	1.03	5.48	4.11	5.10
7	**Profit after interest but before Tax(5-6)**	**487.98**	**108.78**	**1282.38**	**727.00**	**850.67**
8	Exceptional items	0	0	0	0	0.00
9	**Profit(+)/ Loss (-)before Tax(7+8)**	**487.98**	**108.78**	**1282.38**	**727.00**	**850.67**
10	Tax expense	6.59	4	17.13	13.12	39.28
11	Net profit(+) / Loss(-) from Ordinary Activities after Exceptional items(7-8)	481.39	104.78	1265.25	713.88	811.39
12	Extraordinary Item (net of tax expense Rs……..)	0.00	0.00	0.00	0.00	0.00
13	Net Profit (+) Loss (-) for the period	481.39	104.78	1265.25	713.88	811.39
14	Paid-up Equity Share Capital (Face value of the Share shall be indicated)	1605(Rs.10/-)	1370(Rs.10/-)	1605(Rs.10/-)	980(Rs.10/-)	1370(Rs.10/-)
15	Reserve excluding Revaluation Reserves as per Balance Sheet of the Previous Accounting Year					2629.26
16	Earnings Per Share (EPS)(in Rs.)					
	(a) Basic and diluted EPS before Extraordinary items for the period, for the year to date and for the previous year(not to be annualized)	3.01	0.76	7.91	7.28	5.92
	(b) Basic and diluted EPS after Extraordinary items for the period, for the year to date and for the previous year (not to be annualized)	3.01	0.76	7.91	7.28	5.92
17	Public Shareholding					
	Number of Shares	13495870	5941700	13495870	5941700	9036770
	Percentage of share holding	84.09	60.62	84.09	60.62	65.96
18	Promoters and promoter group shareholding **	15.91	19.90	15.91	19.90	18.42
a)	Pledged/Encumbered -Number of shares	Nil	Nil	Nil	Nil	Nil
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil
	-Percentage of Shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil
b)	Non-encumbered	Nil	Nil	Nil	Nil	
	-Number of shares	Nil	Nil	Nil	Nil	4663230
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	100
	-Percentage of Shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	34.04

Notes:

1. The above UnAudited Financial Results, as reviewed by the Audit Committee, have been approved at the meeting of the Board of Directors held on 30th January - 2010.
2. The Company operates only in one segment i.e.: Agri biotech products
3. Shareholders' Grievances: Opening -NIL ,Redressed -NIL , Pending - NIL.
4. The financial results for the quarter ended December ,2009 have been subjected to Limited Review by the Auditors
5. The figures have been rearranged/ regrouped, as necessery.
6. The Company has extended its operations / entered into new areas to enhance its reach.
7. Research Expenditure includes basic research, product development and final stages of product testing at multilocational trials.
8. Approval of the share holders will be sought for alteration of ceratin clauses of Articles in the Articles of Association.
9. During the quarter 23,50,000 Equity Shares of Rs. 10 each for cash at a premium of Rs. 65/- per Share were allotted to a strategic investor & 39,50,000 Warrants convetible into Equity Shares of Rs. 10/- each at a premium of Rs.65 per Warrant. 25 % paid on application, were allotted to Promoter/Others. Both the allotments are in conformity with the prevailing laws.

For and on behalf of the Board of Directors

Date 30.01.2010

sd/-

Place Bangalore

Managing Director